136 related articles for article (PubMed ID: 1848372)
1. Cisplatin chemoprotection and rescue: pharmacologic modulation of toxicity.
Gandara DR; Perez EA; Weibe V; De Gregorio MW
Semin Oncol; 1991 Feb; 18(1 Suppl 3):49-55. PubMed ID: 1848372
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of cisplatin dose intensity: current status and future prospects.
Gandara DR; Perez EA; Phillips WA; Lawrence HJ; DeGregorio M
Anticancer Res; 1989; 9(4):1121-8. PubMed ID: 2683991
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate.
Gandara DR; Wiebe VJ; Perez EA; Makuch RW; DeGregorio MW
Crit Rev Oncol Hematol; 1990; 10(4):353-65. PubMed ID: 2177606
[TBL] [Abstract][Full Text] [Related]
4. Future opportunities in preventing cisplatin induced ototoxicity.
van den Berg JH; Beijnen JH; Balm AJ; Schellens JH
Cancer Treat Rev; 2006 Aug; 32(5):390-7. PubMed ID: 16781082
[TBL] [Abstract][Full Text] [Related]
5. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
6. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
[TBL] [Abstract][Full Text] [Related]
7. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
Hausheer FH; Kanter P; Cao S; Haridas K; Seetharamulu P; Reddy D; Petluru P; Zhao M; Murali D; Saxe JD; Yao S; Martinez N; Zukowski A; Rustum YM
Semin Oncol; 1998 Oct; 25(5):584-99. PubMed ID: 9783598
[TBL] [Abstract][Full Text] [Related]
8. Reduction of tetrachloro(dl-trans)1,2-diaminocyclohexaneplatinum(IV) (tetraplatin) toxicity by the administration of diethyldithiocarbamate (DDTC), S-2(3-aminopropylamino)ethylphosphorothioic acid (WR-2721), or sodium selenite in the Fischer 344 rat.
Carfagna PF; Chaney SG; Chang J; Holbrook DJ
Fundam Appl Toxicol; 1990 May; 14(4):706-19. PubMed ID: 2163338
[TBL] [Abstract][Full Text] [Related]
9. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities.
Gandara DR; Nahhas WA; Adelson MD; Lichtman SM; Podczaski ES; Yanovich S; Homesley HD; Braly P; Ritch PS; Weisberg SR
J Clin Oncol; 1995 Feb; 13(2):490-6. PubMed ID: 7844610
[TBL] [Abstract][Full Text] [Related]
10. A review of the use of chemoprotectants in cancer chemotherapy.
Lewis C
Drug Saf; 1994 Sep; 11(3):153-62. PubMed ID: 7811398
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin dose intensity.
Ozols RF
Semin Oncol; 1989 Aug; 16(4 Suppl 6):22-30. PubMed ID: 2669135
[TBL] [Abstract][Full Text] [Related]
12. Protection of cisplatin-induced neuropathy: recent developments.
Hamers F; Neijt J; Gispen W
Pathol Biol (Paris); 1992 Nov; 39(9):829-30. PubMed ID: 1311436
[No Abstract] [Full Text] [Related]
13. Interventions for preventing neuropathy caused by cisplatin and related compounds.
Albers J; Chaudhry V; Cavaletti G; Donehower R
Cochrane Database Syst Rev; 2007 Jan; (1):CD005228. PubMed ID: 17253547
[TBL] [Abstract][Full Text] [Related]
14. Administration of the cytoprotectant amifostine.
Lindemann K
Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
[TBL] [Abstract][Full Text] [Related]
15. Morphological and electrophysiological study of the effects of cisplatin and ORG.2766 on rat spinal ganglion neurons.
Müller LJ; Gerritsen van der Hoop R; Moorer-van Delft CM; Gispen WH; Roubos EW
Cancer Res; 1990 Apr; 50(8):2437-42. PubMed ID: 2156619
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin: a review of toxicities and therapeutic applications.
Barabas K; Milner R; Lurie D; Adin C
Vet Comp Oncol; 2008 Mar; 6(1):1-18. PubMed ID: 19178659
[TBL] [Abstract][Full Text] [Related]
17. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
Schuchter LM
Eur J Cancer; 1996; 32A Suppl 4():S40-2. PubMed ID: 8976821
[TBL] [Abstract][Full Text] [Related]
18. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer.
Roberts JA; Jenison EL; Kim K; Clarke-Pearson D; Langleben A
Gynecol Oncol; 1997 Nov; 67(2):172-7. PubMed ID: 9367703
[TBL] [Abstract][Full Text] [Related]
19. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Treskes M; van der Vijgh WJ
Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
[TBL] [Abstract][Full Text] [Related]
20. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway.
Wu YJ; Muldoon LL; Neuwelt EA
J Pharmacol Exp Ther; 2005 Feb; 312(2):424-31. PubMed ID: 15496615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
